TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00628784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
Study: NCT03408418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Description: The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
Study: NCT03241277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal treatment
Description: Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
Study: NCT00628784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
Study: NCT00436683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study: NCT01318694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT00436683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: tablet 800mg
Study: NCT03529916

Intervention type: OTHER
Intervention: isolation of endothelial cells precursors in blood
Description: Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.

Intervention type: OTHER
Intervention: isolation of endothelial cells precursors in blood
Description: Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
Study: NCT01318694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALV Placebo
Description: ALV placebo soft gel capsules administered orally
Study: NCT03802994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23 valent pneumococcal polysaccharide vaccine
Description: FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent conjugated pneumococcal vaccine
Description: FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
Study: NCT03241277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal treatment
Description: Scaling and root planning that will be performed with manual curettes or ultrasonic instruments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal treatment
Description: Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
Study: NCT02227069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M518101 Vehicle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Study: NCT00322452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV
Study: NCT01961856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Ticagrelor
Description: Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose
Study: NCT03576404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Pharmacist Care
Description: A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
Study: NCT03831295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody BMS 986178
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given IT
Study: NCT03689491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual feedback training
Description: Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: visual feedback training
Description: Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: 30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
Study: NCT03044119

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant with PRFM
Description: placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dental Implant with PRFM and PBMSCs
Description: placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
Study: NCT01357161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle
Study: NCT04234646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) 2.0 Checklist
Description: The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Patient Navigation (PN)
Description: The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
Study: NCT01335893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
Study: NCT04473274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Receive pioglitazone 15mg - 30mg daily
Study: NCT04265157

Intervention type: PROCEDURE
Intervention: Surgical technique surgical occlusion
Description: Occlusion of hepatoduodenal ligament by clamp or occlusive bands

Intervention type: PROCEDURE
Intervention: Surgical technique surgical occlusion
Description: Occlusion of hepatoduodenal ligament by clamp or occlusive bands
Study: NCT02910401

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus (GMP RV16 HRV-16)
Description: 300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus (GMP RV16 HRV-16)
Description: 300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus (GMP RV16 HRV-16)
Description: 300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
Study: NCT00992199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, Fluorouracil
Description: cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
Study: NCT04544930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapist-guided
Description: Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
Study: NCT03631004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: olanzapine 10 mg is given before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine 10 mg is given before surgery
Study: NCT01331837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
Study: NCT04565444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: * Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone + Protein
Description: * Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: * Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)
Study: NCT01708265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting
Description: In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early mitral valve repair
Description: Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
Study: NCT04008641

Intervention type: OTHER
Intervention: Pediatric consultation's survey
Description: Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
Study: NCT04148196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Description: The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
Study: NCT00721760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study: NCT02748668

Intervention type: OTHER
Intervention: Blood specimen collection

Intervention type: OTHER
Intervention: Blood specimen collection
Study: NCT01384448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Echocardiography
Description: Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography
Description: 64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
Study: NCT00684593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin capsules orally, once daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to Navarixin orally, once daily for 28 days.
Study: NCT03742934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short peptide
Description: Short peptide formula during bowel preparation

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid diet
Description: Liquid diet during bowel preparation
Study: NCT00709683

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00684307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: ER tablet, PO, once daily for a period of 3-9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: ER tablet, PO, once daily for a period of 3-9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: ER tablet, PO, once daily for a period of 3-9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin-K antagonist at INR 2-3
Description: Tablet, PO for a period of 3-9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: ER tablet, PO, twice daily for a period of 3-9 months
Study: NCT01606514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bounce Back Now Website
Description: Bounce Back Now is a web-based psychoeducation and self-help website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bounce Back Now Website
Description: Bounce Back Now is a web-based psychoeducation and self-help website
Study: NCT03268720

Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP low diet
Description: 2 week FODMAP low diet

Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP low diet
Description: 2 week FODMAP low diet

Intervention type: OTHER
Group type: OTHER
Intervention: gluten-free diet
Description: 2 week gluten-free diet

Intervention type: OTHER
Group type: OTHER
Intervention: gluten-free diet
Description: 2 week gluten-free diet
Study: NCT03898154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6